<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11424">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575367</url>
  </required_header>
  <id_info>
    <org_study_id>041-101</org_study_id>
    <secondary_id>P08653</secondary_id>
    <nct_id>NCT00575367</nct_id>
  </id_info>
  <brief_title>Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers</brief_title>
  <official_title>A Single-Center, Open-Label, Randomized Study of the Pharmacokinetics of AzaSite Ophthalmic Solution Versus Vigamox in the Tears of Healthy Volunteers Following a Single Ocular Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the drug concentrations of AzaSite compared to
      Vigamox in tears of healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Concentration of AzaSite and Vigamox in the Tear Fluid Across Six Time Points Ranging From 15 Minutes to 24 Hours Following Administration.</measure>
    <time_frame>15 minutes, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Bacterial Infections</condition>
  <condition>Eye Infections</condition>
  <arm_group>
    <arm_group_label>AzaSite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vigamox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AzaSite (azithromycin ophthalmic solution)</intervention_name>
    <description>One drop ophthalmic solution at Visit 2</description>
    <arm_group_label>AzaSite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigamox (moxifloxacin hydrochloride ophthalmic solution)</intervention_name>
    <description>One drop ophthalmic solution at Visit 2</description>
    <arm_group_label>Vigamox</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have visual acuity, using corrective lenses (no contact lenses) if necessary, in both
             eyes of at least +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study.

          -  Have normal lid anatomy.

        Exclusion Criteria:

          -  Have an abnormal biomicroscopy or ophthalmoscopy exam.

          -  Have a diagnosis of dry eye disease or have experienced any of the dry eye symptoms
             (photophobia, foreign body sensation, itching, burning, pain, dry or grittiness) in
             the past thirty days.

          -  Have used artificial tears in the past thirty days.

          -  Have a diagnosis of on-going ocular infection or lid margin inflammation.

          -  Have ever had penetrating ocular surface or intraocular surgery.

          -  Have a known hypersensitivity to azithromycin, or any macrolide antibiotic or to any
             of the ingredients in AzaSite.

          -  Have had a known hypersensitivity to Vigamox or any fluoroquinolone antibiotics or to
             any of the ingredients in Vigamox.

          -  Have had corneal or lid abnormalities.

          -  Have glaucoma, or Intra Ocular Pressure of 22 mm Hg or greater in one or both eyes.

          -  Have any ocular pathology with the exception of cataracts.

          -  Have a serious systemic disease or uncontrolled medical condition.

          -  Have experienced symptoms of viral or allergic conjunctivitis in the past 30 days.

          -  Have a history of liver or kidney disease resulting in persisting dysfunction.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Haque, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <lastchanged_date>September 20, 2011</lastchanged_date>
  <firstreceived_date>December 14, 2007</firstreceived_date>
  <firstreceived_results_date>August 10, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Karen Kuhn</name_title>
    <organization>Inspire Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AzaSite</title>
        </group>
        <group group_id="P2">
          <title>Vigamox</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AzaSite</title>
        </group>
        <group group_id="B2">
          <title>Vigamox</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="35"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Baseline measures for two subjects were not included in this analysis due to missing data on too many data points. Although the total number of baseline participants was 37, the actual number included in the analysis was 35 subjects, 18 subjects in the Azasite group and 17 in the Vigamox group.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33.9" spread="12.59"/>
                <measurement group_id="B2" value="38.1" spread="13.29"/>
                <measurement group_id="B3" value="36.0" spread="12.92"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of AzaSite and Vigamox in the Tear Fluid Across Six Time Points Ranging From 15 Minutes to 24 Hours Following Administration.</title>
        <time_frame>15 minutes, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol Population</population>
        <group_list>
          <group group_id="O1">
            <title>AzaSite</title>
          </group>
          <group group_id="O2">
            <title>Vigamox</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Concentration of AzaSite and Vigamox in the Tear Fluid Across Six Time Points Ranging From 15 Minutes to 24 Hours Following Administration.</title>
            <units>Âµg/mL</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>15 Minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16.485" spread="22.9971"/>
                  <measurement group_id="O2" value="8.199" spread="15.9873"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>1 Hour</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.007" spread="4.3680"/>
                  <measurement group_id="O2" value="2.221" spread="4.1506"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.966" spread="3.6632"/>
                  <measurement group_id="O2" value="2.985" spread="5.6350"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.558" spread="2.6151"/>
                  <measurement group_id="O2" value="0.603" spread="1.0074"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>8 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.590" spread="4.8111"/>
                  <measurement group_id="O2" value="1.364" spread="2.7629"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>24 Hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.195" spread="0.2558"/>
                  <measurement group_id="O2" value="0.021" spread="0.0449"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AzaSite</title>
        </group>
        <group group_id="E2">
          <title>Vigamox</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI cannot publish or discuss trial results until written communication is received from Inspire Pharmaceuticals, Inc.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Karen Kuhn/ Director</name_or_title>
      <organization>Inspire Pharmaceuticals, Inc.</organization>
      <phone>919 941-9777</phone>
      <email>kkuhn@inspirepharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
